Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday.

Aethlon Medical Price Performance

Shares of AEMD opened at $0.40 on Friday. The firm has a 50-day simple moving average of $0.40 and a two-hundred day simple moving average of $0.48. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $2.35. The stock has a market cap of $5.58 million, a PE ratio of -0.14 and a beta of 1.74.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same period in the previous year, the business posted ($1.30) earnings per share. As a group, sell-side analysts expect that Aethlon Medical will post -1.1 earnings per share for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.